Rogelio Santos, Jr.
Rogelio Santos, Jr. is the co-founder, Chairman, and CEO of Amylex. Under his leadership, he successfully developed and led the company towards its first FDA approval. Santos has also founded companies including a multinational software development and digital media firm, a national real-estate technology services agency, a non-profit organization, and a web-based construction project collaboration platform. He is also recognized as the inventor of a disaster response solution called the Butterfly House providing “folding houses” or rapid deployment shelter systems to disaster survivors.
In 2015, Santos was awarded the Ten Outstanding Young Men (TOYM) Award, the most prestigious award given in the Philippines. He has received two Senate Resolutions as recognition for his achievements. He has received many other notable awards including recognition from the New Jersey-based Ernst & Young and NJ Biz Magazine as one of New Jersey’s top 30 entrepreneurs. He has been featured on TED Talks and featured on major news outlets like the Wall Street Journal, CNN, and Bloomberg.
Andy Stein is a Co-Founder of AEVOLVE, a Swiss company that facilitates alternative financing through its global digital marketplace for biotech and medical innovations called BioSpheres. He also co-founded Amylex, an R&D biotechnology company that developed an FDA-approved nano-molecular medical device for rapid extraction of beta-amyloids in the blood, which may be beneficial for debilitating diseases affected by beta-amyloids, such as Alzheimer’s and Type 2 diabetes.
Prior to his work in biotechnology, Andy was esteemed as ‘The DreaMaker’ for his creative out-of-the-box thinking and unwavering drive in the manifestation of a better world, which he has exemplified in his musical accomplishments as a songwriter and lyricist, and also throughout his vast 20+ years in sales and marketing for an international health and wellness company. Stein’s vision and resourceful contribution have been a reliable driving force behind both companies and his boundless experience in connecting with people has enabled him to bring significant people and financial support to Amylex and AEVOLVE.
Tom Eineker is an executive visionary known for delivering high-value ROI for SAP consulting services. His expertise includes strategy, execution, and optimization of operational support services. Over the last 25 years, his accomplishments include the implementation of SAP best practices and customized solutions for over 500 of the world’s industry-leading Global 2000 clients.
Science & Healthcare
Eustaquio De Ocampo Abay II, MD
Dr. Eustaquio Abay is the founder of Abay Neuroscience Center beginning as a solo practice in 1986 and emerging to become the largest neurosurgery practice in the greater Wichita metropolitan area serving patients nationwide. Dr. Abay is a leading expert and practicing neurosurgeon. Currently serving on several boards in the healthcare, corporate, and non- profit sectors, he was named by Money Magazine as one of the top surgeons of the United States.
Guillermo Tous, PhD
Senior Director of Biopharmaceutical and Pharmaceutical Research and Development with 25-year track record managing and prioritizing multiple simultaneous projects. Served six years as Senior Director for Product Development, Process Development, Formulation Development, Analytical Science, Chemical Development and Protein Development at Stiefel, a GSK company, Barrier Therapeutics and Phyton Biotech, Inc.; five years as Director of Chemistry, Protein Development; and Analytical Biochemistry Research and Development at Phyton Biotech, Inc and MedImmune Inc.; and seven years as Manager of Chemical Development, Analytical Services (CDAS, with overall responsibilities for cGMP compliance and FDA interactions for SNDA filings), and registration services at Bristol-Myers Squibb.
Chinnaswamy Kasinathan, PhD
Dr. Kasinathan is an Associate Professor in the Department of Oral Biology at the University of Medicine and Dentistry of New Jersey. He received his Doctorate Degree at the Postgraduate Institute of Medical Education and Research in Chandigarh, India in 1984. He completed his postdoctoral training in the Department of Physiology and Biophysics at Mount Sinai School of Medicine in New York before joining the Department of Oral Biology at New Jersey Dental School in 1988.
THE NEW PATH TO PATIENT-DRIVEN TREATMENTS AND CURES
Aevolve is a protocol that supports medical innovations from R&D stages to full-scale commercialization, by connecting patients, investors, and scientific innovators.
FOR PATIENTS AND INNOVATORS
This innovation marketplace connects patients and the global community directly with scientific innovators and experts from all over the world to address various stages of the innovation life cycle.
INVESTOR ACCESS TO A BILLION-DOLLAR ECOSYSTEM
This new asset class provides exposure to opportunities in blockchain, free of the risks associated with previous token offerings. Coming soon to the the SIX Swiss Stock Exchange.
AVEX Token & The Aevolve Protocol
Cutting-edge medical science meets blockchain-driven technology to create new opportunities to drive innovation.